TRAILBLAZER 2
I5T-MC-AACI
What follows is a brief summary of the Lilly Phase 3 TRAILBLAZER 2 trial of an anti-amyloid vaccine designed to slow down the progression of disease for individuals with MCI or mild dementia due to Alzheimer's.
*** Through Oct-Nov 2021, this will become an Open-Label Study (ALL on Study Drug, no placebo) for newly enrolling patients
Drug administration -- monthly IV
Age range -- 60-85
MMSE range -- 24-30
Study Duration -- 18 mos. + open label extension
Target population -- Early Alzheimer's (MCI, very mild dementia). Amyloid PET or CSF positive at screening
Mechanism of action -- removes existing amyloid beta block
Randomization split -- 1:1, active : placebo
Type(s) of imaging -- brain MRI, amyloid PET, Tau PET
For more details on this specific trial, visit:
ClinicalTrials.gov
A service of the U.S. National Institutes of Health